Back to News
Market Impact: 0.4
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Source: PR Newswire
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
CSL and Alentis Therapeutics announced an exclusive global agreement under which Alentis will receive an initial payment of US$355 million and could receive up to US$1.2 billion in commercial milestones. The companies will also share global profits; further terms and the product involved are not provided in the available article text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
More News
- ‘Unwelcome and unsafe’: Why Japanese companies are retreating from China at a record pace
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace
- Can America Break China’s Grip on Rare Earths?
- Tom Cruise suffers one of the worst movie debuts of his career. Reviews were so bad Warner Bros. ran ‘decide for yourself’ ads
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report